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South Africa. Tiris is important for all women, but perhaps 
more so for women of low socio-economic status who may 
have little else by way of affirmation should their family life 
breakdown. 
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SHORT REPORT 
SIDE-EFFECTS OF ORAL 
MISOPROSTOL IN THE THIRD 
STAGE OF LABOUR- A 
RANDOMISED PLACEBO-
CONTROLLED TRIAL 
G Justus Hofmeyr, V Cheryl Nikodem, Marinda de Jager, 
Andrew Drakely 
Background. Misoprostol, an irlexpensive, stable, orally active 
prostaglandirl analogue, has been suggested for use ir1 the 
prevention of postpartum haemorrhage. Potential side-effects, 
however, need to be quantified. 
Objective. To compare the rate of postpartum shivering and 
pyrexia following oral misoprostol 600 llg and placebo. 
Design. A double-blind placebo-controlled trlal. Women ir1 
labour were randomly allocated to receive either misoprostol 
600 llg orally or placebo after delivery. Conventional 
oxytocics were given immediately if blood loss was thought 
to be more than usual. Side-effects were recorded. 
Postpartum blood loss ir1 the first hour was measured by 
collection ir1 a special flat plastic bedpan. 
Setting. The labour ward of an academic hospital ir1 
Johannesburg, with 7 000 deliveries per annum. 
Main outcome measures. Shivering and pyrexia. 
Results. The groups were well matched. Misoprostol use was 
associated with more shivering (44% versus 11%, relative risk 
(RR) 4.03, 95% confidence irlterval (0) 2.85 - 5.70), pyrexia 
~ 37.8°C (38% v. 6%, RR 6.23, CI 3.89- 9.97), 1-hour systolic 
blood pressure~ 140 mmHg (33% v. 25%, RR 1.32, a 1.03 -
1.70), and diastolic blood pressure ~ 90 mmHg (10.5% v. 3.0%, 
RR 3.44, a 1.67 ~ 7.11). There were no other significant 
differences. The study was not designed to be large enough 
to assess a difference ir1 blood loss~ 1 000 rnl (9% v. 9.7%, 
RR 0.93, a 0.56 - 1.53). Possible effects on blood loss may 
have been obscured by the lesser use of additional oxytocics 
ir1 the misoprostol group (14% v. 18%, RR 0.78, CI 0.54 - 1.13). 
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Conclusions. This study has shown the association of 
postpartum oral misoprostol 600 J.Ig with shivering, pyrexia 
and hypertension. The increased blood pressure, as for the 
trend towards increased abdominal pain, may be secondary 
to the uterotonic effect of misoprostol. Large randornised 
trials are needed to assess the effectiveness of misoprostol in 
the prevention of postpartum haemorrhage, against which 
the disadvantages demonstrated here can be weighed. 
S Afr M£d I 2001; 91; 432-435. 
The use of misoprostol, an inexpensive, stable, orally active 
prostaglandin analogue, for the prevention of postpartum 
haemorrhage, was first reported in 1996.' If effective, this 
therapy would have profound implications for the health of 
childbearing women worldwide. A limiting factor may be side-
effects of rnisoprostoF In a preliminary randomised trial, we 
observed shivering in 19% of puerperal women who received 
oral misoprostol 400 J.Ig, compared with 5% of those who 
received placebo treatment.' As shivering was not a primary 
outcome of the latter study, underreporting may have occurred. 
We have therefore conducted a prospective, randornised, 
placebo-controlled trial specifically to assess the side-effects of 
misoprostol use after delivery. 
pATIENTS AND METHODS 
The study protocol was approved by the Committee for 
Research on Human Subjects of the University of the 
Witwatersrand. Women in labour at Coronation Hospital, 
Johannesburg, were asked to participate in the study, and to 
sign informed consent. Baseline data were recorded. 
Immediately after delivery the women were asked to swallow 
three tablets directly from the next in a series of numbered, 
opaque test tubes, with a sip a water. The tablets were either 
misoprostol 200 J.Ig or placebo tablets similar in size and colour 
but not shape. Efforts to obtain identical placebo tablets were 
unsuccessful. This method of blinding proved to be effective. 
The containers were ordered according to a computer-
generated random sequence, in balanced blocks of 18. The 
placenta was removed by cord traction once the uterus was 
palpated to have contracted firmly. 
Within a minute after delivery, linen soiled with amniotic 
fluid was removed, a fresh, disposable absorbent linen saver 
sheet with plastic backing was placed under the woman, and a 
low-profile wedge-shaped plastic 'fracture' bedpan was slid 
under her buttocks. When active bleeding had stopped, any 
blood dots were expressed from the uterus, the bedpan was 
removed and a sanitary towel was applied. The blood in the 
bedpan was measured in a measuring jug. One hour after 
delivery, any bloodstained linen savers and sanitary towels 
were placed in a plastic bag and weighed in grams. The known 
dry weight of the linen savers and sanitary towels was 
subtracted to give the approximate volume of blood in 
rnillilitres. This was added to the measured blood volume from 
the bedpan to give the total measured blood loss in the first 
hour after delivery. 
Because conventional oxytocics were not given routinely, the 
protocol required that dose observation be maintained, and 
conventional therapy be given immediately if the bleeding was 
considered to be more than usual. The caregiver could choose 
to use intramuscular Syntometrine 1 ampoule or oxytocin 
10 IU, or in more severe cases an intravenous infusion of 
oxytocin 20 IU in 1 000 rnl saline. 
All data were entered onto a database (Epilnfo 6) for 
analysis. The randomisation code was broken only after entry 
and checking of data. Comparisons w ere by the chi-square test 
with Yates' correction or Fisher's exact probability test if any 
cell was < 5, and relative risks with Taylor Series 95% 
confidence intervals. 
R ES ULTS 
There were no withdrawals after randomisation and all 
outcomes were analysed in the allocated group. 
The randomisation process was successful in producing well-
matched groups (Table I). The outcome variables are shown in 
Table II. Shivering, pyrexia;::>: 37.8°C and hypertension were 
significantly more common in the misoprostol group. There 
was somewhat less frequent use of conventional oxytocics in 
the rnisoprostol group. 
Table I. Comparison of baseline variables between women 
randomly allocated to receive misoprostol 600 pg or placebo for 




















3 076 (528) 
Results are expressed as mean values (standard deviation) or numbers (%). There 
were no statistically significant differences. 
DISCUSSION 
The use of placebo treatment was considered acceptable by the 
University Ethics Committee, specifically within the context of 
a research environment in which blood loss was closely and 
accurately monitored, and conventional oxytocics were 
administered as soon as blood loss was thought to be more 
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women with negative 
observed outcomes (%) 
Primary outcomes 
Shivering 300 133 (44) 
Temperature ~ 37.8°C 299 114 (38) 
Temperature ~ 40°C 299 1 (0.3) 
Secondary outcomes 
Nausea 300 5 (1.7) 
Vomiting 300 4 (1.3) 
Diarrhoea 300 1 (0.3) 
Abdominal pain 300 47 (15.7) 
Blood pressure at 1 hour 300 2 (0.7) 
Systolic~ 140 mmHg 299 100 (33) 
Diastolic ~ 90 mmHg 296 31 (10.5) 
Blood loss ~ 1 000 ml 300 27 (9) 
Additional oxytocic needed 300 42 (14) 
Third stage ~ 30 min 299 6 (2) 
Manual removal of placenta 300 2 (0.7) 
Blood transfusion 299 1 (0.3) 
Results are expressed as numbers (%). 
RR = relative risk; 0 = confidence inteJVal 
brisk than usual. Placebo use has also been considered 
acceptable in a recent Swedish trial.' 
Two previous reports1.2 have suggested that postpartum 
misoprostol causes shivering in as many as 60% of women, but 
these studies lacked the control groups necessary to quantify 
this effect. After completing the current study, we participated 
in a World Health Organisation multicentre pilot trial 
comparing misoprostol 600 )lg and 400 )lg and Syntocinon 10 
units intramuscularly.' Although different cut-off points were 
chosen, both trials documented a clear thermogenic effect of 
puerperal misoprostol. In only one case in the current trial did 
the temperature exceed 40°C, and in no case was the 
temperature problematic. However, it is most important that 
clinicians be aware of this side-effect to avoid unnecessary 
investigation or treatment of 'unexplained' postpartum 
pyrexia. 
This is the first randomised trial to show an increase in 
postpartum hypertension with misoprostol. As misoprostol in 
non-pregnant hypertensive patients is associated with slight 
lowering of blood pressure," the most likely explanation for this 
finding is that blood pressure was increased as a result of 
increased uterine contractility. Physiological studies have 
demonstrated a clear uterotonic effect of misoprostol in the 
puerperium.' Similarly, the near-significant increase in 
abdominal pain is likely to reflect increased uterine contraction. 
One possible method of reducing side-effects of misoprostol 
May 2001, Vol. 91, No. 5 SAMJ 
Placebo 
o. of women 
women with negative 
















33 (11) 4.03 2.85 - 5.70 0.0000 
18 (6.1) 6.23 3.89 - 9.97 0.0000 
0 (0) 1.00 
1 (0.3) 5.00 0.59-42.5 0.22 
2 (0.7) 2.00 0.37 - 10.8 0.68 
1 (0.3) 1.00 0.06-15.9 1.00 
31 (10.3) 1.52 0.99-2.32 0.07 
2 (0.7) 1.00 0.14 - 7.05 1.00 
75 (25) 1.32 1.03-1.70 0.04 
9 (3.0) 3.44 1.67 - 7.11 0.0006 
29 (9.7) 0.93 0.56- 1.53 0.88 
54 (18) 0.78 0.54-1.13 0.22 
3 (1) 1.99 0.50-7.87 0.50 
2 (0.7) 1.00 0.14-7.05 1.00 
2 (0.7) 0.50 0.05 -5.50 1.00 
in the third stage of labour is use of the rectal route.•·• 
No conclusions should be drawn from the lack of a 
significant reduction in postpartum haemorrhage in this study, 
firstly because the numbers s tudied were not adequate to 
detect a modest reduction, and secondly because the ready use 
of conventional oxytocics, which were required more 
frequently in the control group, is likely to have obscured any 
benefit from misoprostol. The potential benefit of misoprostol 
may be greater in an environment in which conventional 
oxytocics are not available. 
CONCLUSIONS 
This study has quantified certain side-effects of postpartum 
misoprostol. It is essential for clinicians who use misoprostol in 
the postpartum period to be aware of these side-effects. Very 
large randomised trials, such as the trial currently being 
undertaken by the World Health Organisation, are needed to 
determine the effectiveness of oral misoprostol in the 
prevention of postpartum haemorrhage, against which the 
disadvantages of the side-effects documented in this study can 
be weighed. 
We acknowledge support from the South African Medical 
Research Council and the University of the Witwatersrand, and the 
excellent assistance of the nursing staff at Coronation Hospital. 
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• Kangaroo Mother Care 
Restoring the Original Paradigm for 
Infant Care and Breastfeeding 
Kangaroo Mother Care is a 
method of care for all 
newborn babies, but espe-
cially prematures. This is the 
eagerly awaited original video 
of Dr Nils Bergman's highly 
popular talks on the subject. 
The video provides the latest 
up-to-date research and 
evidence to prove that the 
newborn thrives best in its 
original "rightful" place- on its 
mother's chest. Kangaroo 
Mother Care has the 
following vital components: 
Skin to skin contact 
KANGAROO 
MOTHER CARE 
The naked baby is placed Dr Nils 2000 
against the mother's skin, 
where the temperature is perfectly controlled all the time. A 
mother's temperature will naturally rise 2° C to warm a cold 
baby. The baby's breathing is markedly improved. 
Breastfeeding 
The baby is given the full benefits of the perfect food. 
Mother's milk contains the exact proteins required, and for 
premature babies, the protein content increases automatically 
for better growth. The composition is such that the baby 
rarely suffers colic and constipation. Mother's milk contains 
antibodies against infection. 
Never separate mother and child 
The stress of separation causes hormones to be released 
which interfere with digestion and all other normal functions of 
the baby's body: the baby is in survival mode rather than 
growing normally. Kangaroo Mother Care enables the baby 
to relax, and improves the heart rate and temperature. High 
levels of stress hormones can have permanent adverse 
effects on the baby's brain, resulting in behaviour disorders 
and lower IQ later in life. 
Mother's love 
Kangaroo Mother Care leads to better bonding between 
mother and baby, and empowers the mother, who knows 
instinctively that she is giving her baby superb nursing care 
for a secure and healthy future. 
The video provides full details on why Kangaroo Mother 
Care works, and why it is so important for all newborn 
babies. It is intended for doctors and health workers dealing 
with healthy and "at risk" mothers-to-be , and for prospective 
mothers and fathers. Kangaroo Mother Care is now official 
government policy in the Western Cape, and is soon to be 
adopted by other provinces. 
Order your copy of this life-changing video for R150 
including VAT and postage. 
Orders: The South African Medical Association 
Private Bag X1, Pinelands 7430. 
Tel (021) 531-3081, fax (021) 531-4126 
E-mail: j~dom@samedical.org 
